• drapreau en
  • drapreau fr

  • Programme & abstracts
  • Programme général


    09:00 - 09:30 - Liquid Biopsy: Technologies and clinical applications
    Klaus PANTEL, University Medical Center Hamburg-Eppendorf, Germany
    09:30 - 10:00 - Influence of the tumor environment on cancer cell metabolism
    Matthew VANDER HEIDEN, Koch Institute at MIT, United States
    10:00 - 10:15 - PGC-1alpha controls an onco-metabolic program to limit prostate cancer aggressiveness
    Frederic BOST, INSERM U1065, C3M, France
    10:15 - 10:45 - Metabolic flexibility and mitochondrial OxPHOS activity in the drug resistance of leukemia
    Jean-Emmanuel SARRY, Cancer Research Center of Toulouse - UMR1037 Inserm/Université Toulouse III-Paul Sabatier, France
    10:45 - 11:15 - Coffe break - Poster session
    11:15 - 11:30 - Periprostatic adipose tissue promotes prostate cancer invasion: role of oxidative stress & regulation by obesity
    Aurélie TOULET, IPBS, France
    11:30 - 11:45 - Na+ leak governs pacemaking activity of cancer cells required for the metastatic disease development
    Oksana IAMSHANOVA, Laboratory of Cell Physiology, INSERM U1003, University of Lille, France
    11:45 - 12:15 - A mitochondrial switch promotes tumor metastasis
    Pierre SONVEAUX, University of Louvain (UCL) Medical School, Belgium
    12:15 - 12:20 - InvivoGen / STING tumors for immunotherapy
    Eric Perouzel, ,
    12:20 - 12:25 - I.Céram / Porous alumina ceramic as a vector for local treatment for bone infection or bone tumor
    Christelle Arico, ,
    12:25 - 12:30 - Urosphère / Urosphere/uroleads : your oncology partners
    Sophie Chabot, ,
    12:30 - 12:35 - Vita API / Selenium-enriched Arthrospira platensis as new vector for anticancer drug delivery
    Catherine Riva, ,
    12:35 - 12:40 - Inovotion / A Unique In Vivo Assay for Your Oncology Drug Candidates
    Arnaud Peyronnier, ,
    12:40 - 12:45 - Essen Bioscience / Live Imaging and Cell Analysis for Immuno-oncology Studies, How the IncuCyte Empowers Cell Based Research
    Jean-Baptiste Pénigault, ,
    14:00 - 14:30 - Maintaining Nature’s Perfection: the impact of DNA repair on sustained health
    Jan H.j. HOEIJMAKERS, Dept. of Genetics, Erasmus MC, Rotterdam, Netherlands
    14:30 - 15:00 - Cellular responses to DNA damage: from mechanistic insights to applications in cancer therapy
    Stephen JACKSON, Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, United Kingdom
    15:00 - 15:15 - Cell fusion contributes to sarcoma formation and progression
    Lucile DELESPAUL, Cancer Research Center of Toulouse, France
    15:15 - 15:45 - Targeting the replication stress response in cancer
    Mark O'Connor, Chief Scientist, Oncology Head of DNA Damage Response Biology Innovative Medicines and Early Clinical Development, AstraZeneca,
    15:45 - 16:15 - Coffe break - Poster session
    16:15 - 16:45 - Chromatin and Chromosome dynamics during DNA Double Strand break repair
    Gaelle LEGUBE, CBI_ LBCMCP_University of Toulouse, France
    16:45 - 17:00 - Post-transcriptional regulation of mRNA location and translation controls oncogene expression in lymphocytes.
    Manuel Daniel DIAZ-MUNOZ, Centre de Physiopathologie Toulouse-Purpan, INSERM UMR1043 / CNRS U5282, France
    17:00 - 17:30 - CSA/CSB, an ubiquitin-proteasome complex in transcription coupled repair?
    Jean-Marc EGLY, Dept of Functional Genomics and Cancer, IGBMC, CNRS/INSERM/University of Strasbourg,
    09:00 - 09:30 - Context-dependent roles of polycomb repressors in cancer and development
    Maarten van Lohuizen, NKI Amsterdam, Netherlands
    09:30 - 10:00 - Expression and function of Long non coding RNAs in Acute Myeloid Leukemia
    Ramiro GARZON, The Ohio State University, United States
    10:00 - 10:15 - Control of gene expression in senescence through transcriptional read-through of convergent protein-coding genes
    Estelle NICOLAS, LBCMCP, France
    10:15 - 10:45 - Coffe break - Poster session
    10:45 - 11:15 - Functional long noncoding RNAs as cancer drivers
    Maïte Huarte, PRINCIPAL INVESTIGATOR LncRNAs and Gene Regulation in Cancer cima. University of Navarra,
    11:15 - 11:30 - A noncoding function of TYRP1 mRNA promotes melanoma growth
    Marie-Dominique GALIBERT, Institut de Génétique et Développement de Rennes, CNRS UMR6290, Université de Rennes, France
    11:30 - 12:00 - Peptides produced by apparently non-coding RNAs in the control of embryonic development and adult stem cells
    François Payre, CNRS Centre de Biologie du Développement Université Paul Sabatier de TOULOUSE CNRS UMR 5547,
    12:00 - 12:05 - Institut de Recherche Pierre Fabre / Pierre Fabre Oncology Presentation
    Anna KRUCZYNSKI, ,
    12:05 - 12:10 - 10X genomics / Single Cell Analysis with 10x Genomics
    Mickael Ploquin, ,
    12:10 - 12:15 - GamaMabs / GM102, a first-in-class immuno-enhancer antibody targeting AMHRII
    Stéphane Degove, ,
    12:15 - 12:20 - Antineo / Optimize and Accelerate the PRECLINICAL PHASE of YOUR ANTICANCER AGENT thanks to our reactivity our expertise
    Chloé Grasselly, ,
    12:20 - 12:25 - Miltenyi Biotec / Immuno-Oncology – Activities and solutions offered by Miltenyi Biotec
    Guillaume Lay, ,
    12:25 - 12:30 - Acobiom / Acobiom : A new approach for precision medicine in pancreatic cancer
    Didier Ritter, ,
    12:30 - 12:35 - LGC / ATCC Advanced Cancer Models
    Romuald Menth, ,
    14:15 - 14:45 - Natural circulating dendritic cells: Key for antitumor immunity?
    Jolanda de Vries, ,
    14:45 - 15:00 - Regulation of immune checkpoint expression
    Don-Marc FRANCHINI, INSERM, France
    15:00 - 15:30 - Identifying high-avidity and high-quality individual T lymphocytes in cancer patients
    Nathalie RUFER, Department of Oncology, Lausanne University Hospital Center and University of Lausanne, Lausanne, Switzerland, Switzerland
    15:30 - 16:00 - Coffe break - Poster session
    16:00 - 16:15 - Machine learning unveils sculpturing of CD8+ T cell compartment by tumor progression predictive of need for therapy
    Pauline GONNORD, INSERM UMR1037, France
    16:15 - 16:45 - Tumor-associated HEVs: specialized blood vessels for lymphocyte entry into tumors
    Jean-Philippe Girard, Institut de Pharmacologie et de Biologie Structurale (IPBS), CNRS-Université de Toulouse III,
    16:45 - 17:00 - Monitoring PD-L1 expression on circulating tumor cells (CTCs) and circulating myeloid derived-suppressor cells (MDSC) during anti-PD1 therapy
    Myriam DELAUNAY, CHU Larrey, Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, Toulouse, France, France
    18:00 - 20:00 - Immunothérapies : de nouveaux traitements porteurs d'espoir
    Maha Ayyoub, ,
    18:00 - 20:00 - La prévention active du cancer
    Cyrille Delpierre, ,
    18:00 - 20:00 - Y-a-t-il une part de hasard dans les cancers ?
    Gilles Favre, ,
    09:00 - 09:30 - Jim Metz, ,
    09:30 - 10:00 - Gillies McKenna, ,
    10:00 - 10:15 - Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics
    Fabien DESPAS, Toulouse University Hospital, France
    10:15 - 10:30 - Immunotherapy against melanoma by pIRE-IL12 Gene electrotransfer (GET): a pre-clinical investigation
    Muriel GOLZIO, IPBS-CNRS, France
    10:30 - 11:00 - Coffe break - Poster session
    11:00 - 11:15 - Translation to the clinic of EVT801: A novel immune-oncology agent for addressing innate-driven immunosuppression into the tumor microenvironment and expand patient population responding to immune checkpoint therapies
    Pierre FONS, EVOTEC, France
    11:15 - 11:30 - Reverse immunosuppression and metastasis formation in pancreatic cancer through pharmacological targeting of cancer associated fibroblasts
    Remi SAMAIN, INSERM - CRCT, France
    11:30 - 12:00 - Overcoming resistance to targeted therapies in lung cancer
    Julien Mazières, ,
    12:00 - 12:05 - Oncomedics / Functional assay to personalized all cancer treatment for all patient
    Christophe Lautrette, ,
    12:05 - 12:10 - Vect-Horus / Targeted delivery to Tumors via Receptor Mediated Transport - Radiotherapy and Imaging
    Cédric Malicet, ,
    12:10 - 12:15 - Chromalys / Micro-technology for tumor detection and tracking during radiotherapy
    Marc Verelst, ,
    12:15 - 12:20 - Easy Chelators / Innovative Radiopharmaceuticals to fight against cancer
    Jean-Marc Joumier, ,
    12:20 - 12:25 - Screencell / Unique Medical device (CE-IVD) for capturing and harvesting circulating tumor cells (CTCs), liquid biopsy of cancer: Clinical applications
    Linda Benali Furet Naoual, ,
    12:25 - 12:30 - Medexprim / Unleash the potential of biomedical images archives and associated data for research
    Karine Seymour, ,
    14:00 - 14:30 - Precision medicine for melanoma: are we there yet?
    Richard MARAIS, Cancer Research UK Manchester Institute, The University of Manchester, UK, United Kingdom
    14:30 - 14:45 - SLITRK6 : new target for the treatment of BRAF-mutant metastatic melanoma ?
    Magdalena POHORECKA, U1037 INSERM CRCT - Centre de Recherche en Cancérologie de Toulouse, France
    14:45 - 15:15 - Céleste Lebbé, ,
    15:15 - 15:45 - Coffe break - Poster session
    15:45 - 16:15 - Dermatologic reactions to immune checkpoint inhibitors
    Vincent Sibaud, ,
    16:15 - 16:30 - Targeting sphingosine kinase-1 enhances anti-melanoma immune response and improves efficacy of immune checkpoint blockade
    Caroline IMBERT, CRCT, France
    16:30 - 17:00 - Combining TNF-targeting antibodies to immune checkpoint inhibitors in melanoma
    Nicolas Meyer, Head of Skin Cancer Unit, Toulouse University Cancer Institute ; Anne Montfort, Cancer Research Center of Toulouse (CRCT- UMR 1037 Inserm /Université Toulouse III),
    Xavier Faure et Axel Wiegandt, Agence Régionale de Santé d’Occitanie

    Problématique de la coordination ville-hôpital en cancérologie, introduction autour du futur Programme Régional de Santé
    Maurice Bensoussan, Président, URPS Médecins, Occitanie Michel Combier, Secrétaire général, URPS Médecins, Occitanie

    L’apport d’un réseau de santé dans la coordination ville hôpital : exemple de Reso82
    Sabine Braun, IDE coordonnatrice, Reseo82, Montauban

    Le lien ville/hôpital autour de cas clinique
    • Cas complexe en hémato
    Dominique Yerle, IDE, IUCT-Oncopole, Toulouse Pascale Cazaneuve, URPS Infirmiers, Toulouse
    • Prescription de thérapies ciblées orales et adhésion aux traitements
    Véronique Flanzy, Pharmacienne, IUCT-Oncopole, Toulouse Intervenant à définir, Pharmacien d’officine, Ville*
    • Gestion effets secondaires & immunothérapie à domicile
    Philippe Houyau, Oncologue, Clinique Claude Bernard, Albi*
    Pierre Boyer, Médecin Généraliste, Pins-Justaret

    Les bonnes pratiques de la coordination ville/hôpital
    Iphigénie Korakis, Médecin Généraliste, IUCT-Oncopole, Toulouse

    Etat des lieux des cartes de coordination mise en place en ville
    Pascale Cazaneuve, URPS Infirmiers, Toulouse Jean-Michel Pomies, URPS Pharmaciens, Toulouse
    The specialized DNA polymerase Kappa required to stabilize the checkpoint kinase Chk1
    Marina DALL'OSTO , Cancer Research in Cancerology of Toulouse - INSERM, France
    Targeted Magnetic Intra-Lysosomal Hyperthermia produces lysosomal reactive oxygen species and causes Caspase-1 dependent cell death of cancer cells.
    Véronique GIGOUX, INSERM ERL1226, France
    Circulating DNA is a marker of aggressivity in Pancreatic Ductal Adenocarcinoma
    Fernanda RAMOS, CRCT Inserm, France
    Tobacco smoke, genes involved in the metabolism of xenobiotics and breast cancer risk
    Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small molecule inhibitors for cancer immunotherapy
    Pierre FONS, EVOTEC, France
    Proteomics and Metabolomics for Mechanistic Insights and Biomarker Discovery in Cancer Disease
    Ontogenic and lineage-specific DNA cytosine demethylation at the IgH constant locus
    Chloé OUDINET, IPBS UMR 5089 UPS Toulouse, France
    Long-range effect of the immunoglobulin heavy chain super-enhancer
    Joana SANTOS, IPBS, France
    Exposure to chlordecone leads to transgenerational effects in murine prostate tissue
    Fatima SMAGULOVA , Inserm U1085/IRSET, France
    Specific detection of the Thomsen-Friedenreich antigen by Xerocomus Chrysenteron Lectin : an in vitro and in vivo study for imaging epithelial ovarian cancer
    Mathilde COUSTETS, Urosphere / Institute of Pharmacology and Structural Biology, France
    Aggressive PDAC with high levels of circulating DNA requires PI3K isoform alpha to accelerate metastatic disease
    Benoît THIBAULT, INSERM - CRCT - Equipe 17, France
    A phosphoproteomic screening reveals a novel combinative therapeutic strategy to exploit the redundancy of Class I PI3Ks in pancreatic cancer.
    The CINSARC signature predicts clinical outcome in multiple cancer types
    Tom LESLUYES, Cancer Research Center of Toulouse, France
    Preclinical study of new potential anticancer agent derived from [188Re]rhenium Nitro-Imidazole ligand loaded 5th generation poly-L-Lysine dendrimer.
    GemciTest, an innovative and sustainable IVD in pancreatic cancer treatment to improve patient quality of life, patient overall survival and healthcare cost saving
    David PIQUEMAL, ACOBIOM, France
    Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP)
    Frédérique FALLONE, IPBS CNRS Toulouse, France
    Exosome based therapy in advanced breast and pancreatic cancer
    Sébastien JAULIAC, INSERM U976, France
    AsiDNA and HDAC inhibitors: a cross-potentiation team working to kill tumor cells
    Françoise BONO COLOMBIÉ, onxeo, France
    Toll-like Receptor 3 suppression as an escape mechanism to apoptosis associated with poor prognosis in hepatocarcinoma
    Nadim FARES, cancer research centrer of Lyon/ Toulouse Hospital, France
    Role of the class IA PI3K p110beta subunit in pancreatic cancer
    Silvia ARCUCCI, Inserm, France
    Characterization of hTERT-immortalized Prostate-derived Stromal and Epithelial Cells: an Authentic in vitro Model for Tumour Microenvironment Studies
    Romuald MENTH, ATCC-LGC, France
    Environmental risk factors and breast cancer at wilaya of Setif
    Hadjira CHAOUCHE, Department of Epidemiology and Preventive Medicine - CHU Setif Algeria, Algeria
    The tyrosine kinase NPM-ALK mediates malignant transformation of normal human CD4 T lymphocytes
    Nina CAILLET, CRCT - Inserm UMR1037, France
    ‘TargetDBR’ –Exploiting synthetic lethal, high content and functional cellular reporter assays to accelerate DNA repair targeted drug discovery
    Francois AYMARD, Evotec, France
    Study of ORAI channel remodelling
    Alexandre BOKHOBZA, INSERM U1003, France
    Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFR? activation.
    Jean-Philippe HUGNOT, INSERM U1051, France
    Application of mental training in a patient with breast cancer subjected to radiation therapy. Case study.
    Anna SERWETA, University School of Physical Education in Wroclaw, Poland
    The efficiency of photodynamic therapy mediated by curcumin against human amelanotic melanoma in vitro
    Stanislaw KWIATKOWSKI, Wroclaw Medical University, Poland, Poland
    Predictive factors and impact on overall survival (OS) and disease-free survival (DFS) of the tumor regression grade (TRG) of resected colorectal liver metastases (CRLM) after neoadjuvant chemotherapy (NACT).
    Charlotte MAULAT, CHU Toulouse, France
    Fibroblastic FAK controls pancreatic cancer metastasis by enhancing extracellular matrix remodeling
    Christine JEAN, Cancer Research Center of Toulouse (CRCT), team 6 “Protein synthesis & secretion in carcinogenesis”,, France
    Phosphoantigenic activation of Vg9Vd2 T lymphocytes: involvement of RHOB in a lung cancer model
    Chloé LAPLAGNE, CRCT U1037, France
    eIF4E3, a regulator of monocytic differentiation in AML?
    Amandine ALARD, CRCT, INSERM , France
    Long non coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature in NPM1-mutated patients
    Morgane GOURVEST, Cancer Research Center of Toulouse/ Université Toulouse III Paul Sabatier, France
    Fibroblastic FAK activity modifies PDAC microenvironment
    Sonia ZAGHDOUDI, Cancer Research Center of Toulouse (CRCT), team 6 “Protein synthesis & secretion in carcinogenesis”,, France
    Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (MEDITREME)
    Francois GHIRINGHELLI, centre georges francois leclerc, France
    Extrapulmonary large Cell Neuroendocrine Carcinoma of the nasal cavity: A Case Report and Review of the Literature
    Chaimaa LAHMAMSSI, chu ibn rochd, Morocco
    Guy TRAN VAN NHIEU, CIRB - Collège de France, France
    Assia ASRIR, IPBS, France
    Single cell RNA-seq analysis of High Endothelial Venules (HEVs): blood vessels that mediate lymphocyte entry into lymph nodes and tumors
    Claire TARDIVEAU, IPBS-CNRS, UMR 5089, France
    CRISPR/Cas9 applied to drug discovery at Evotec
    Francois AYMARD, Evotec, France
    Photobiomodulation in the treatment of pediatric oral mucositis: a feasibility study
    Emmanuelle NOIRRIT-ESCLASSAN, CHU Toulouse, France
    Time trends of cancer incidence and survival in Setif, Algeria, 1986–2010.
    Hadjira CHAOUCHE, Laboratory of Environment and Health, Setif University, Algeria, Algeria
    Variation of exon 11 of the BRCA1 gene in patients with familial breast cancer at the Mohammed VI center for the treatment of cancers
    Ahmadaye IBRAHIM KHALIL, laboratoire de Physiopathologie et genetique Moleculaire, Morocco
    Inflammatory breast cancer: experience of center Mohammed VI for the treatment of cancers
    Ahmadaye IBRAHIM KHALIL, Registry Cancers Of Great Casablanca - Morocco , Morocco
    mélanome malin primitif : à propos d'un cas et revue de la littérature
    Ilham KHALFAOUI, chu ibn rochd casablanca maroc, Morocco
    Cancer in Setif area: Incidence, trend, survival and political impact
    Hanane BENTURKIA, Laboratory of Environment and Health, Setif University, Algeria, Algeria
    A new E3 ubiquitin ligase regulates the immune response in colon cancer
    Spinner CAMILLE, Institut de Pharmacologie et Biologie Structurale - CNRS UMR 5089, France
    Dysregulated IL-18 critically drives immunosuppression in the multiple myeloma microenvironment.
    Ludovic MARTINET, inserm, France
    Mechanisms antagonizing Ku at single-ended DNA double-strand breaks
    Sébastien BRITTON, IPBS CNRS-University of Toulouse, France
    Tumor-initiating and stroma-associated tumor cells within osteosarcoma, a primary bone tumor in adolescent and young adults
    Valérie TRICHET, INSERM UMR1238 Université de Nantes, France
    Hypofractionated accelerated whole breast irradiation for early breast cancer; randomized clinical trial of cosmetic outcome and safety
    Roham SALEK, Mashhad University of Medical Sciences, Iran
    Exploring a new function for cytidine deaminase in pancreatic cancer metabolism
    Audrey FRANCES, CRCT, France
    Large cell neuroendocrine carcinoma of the larynx: A case report
    Sara BELKHEIRI, CHU casablanca service d'oncologie radiothérapie, Morocco
    Phenotypic characterization of a drug tolerant state induced by targeted therapy in EGFR-mutated lung cancer cells.
    Sarah FIGAROL, Cancer Research Center of Toulouse - Team 3, France
    A new role for the E3 ubiquitin ligase TRIP12 in mitosis and genomic stability in pancreatic cancer
    Dorian LARRIEU, Equipe 10 CRCT, France
    Development of an anti-TAM antibody for anticancer therapies
    Julie BORDENAVE, CRCT, France
    Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC
    Nicolas GUIBERT, Toulouse University Hospital, France
    Generation of the Cancer Pathway Prototype - a platform for predictive cancer pathway modeling
    Tania SORG, PHENOMIN-ICS, France
    La relation entre l’accompagnement infirmier et l’acceptation de la nouvelle image corporelle des patientes mastectomisées
    Irradiation-induced transdifferentiation of Glioblastoma Stem Cells into endothelial cells
    Pauline DESHORS, INSERM U1037 CRCT, France
    Michel POPIELARZ, PerkinElmer, France
    Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
    Virginie GOUBERT, PERKIN ELMER, France
    Reversible growth arrest of 3D tumor spheroids stored in oxygen absorber-induced anoxia
    Aurélie GOMES, ITAV CNRS Université de Toulouse, France
    Gap junctions contribute to anchorage-independent clustering of breast cancer cells
    Fabien GAVA, ITAV CNRS Université Toulouse, France
    Mechanical stress controls the orientation of nuclei and cell division in 3D tumour spheroids
    Valérie LOBJOIS, ITAV, CNRS-University of Toulouse, France
    Evolution of Barrett’s Esophagus through space and time at single-crypt and whole-biopsy levels
    Pierre MARTINEZ, Centre de Recherche en Cancérologie de Lyon, France
    Long non coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature in NPM1-mutated patients
    Morgane GOURVEST, Cancer Research Center of Toulouse/ Université Toulouse III Paul Sabatier, France
    TNF alpha Receptor 1 Promoter Gene Polymorphisms and Susceptibility to Gastric Cancer Related to H. Pylori Infection in Moroccan Population
    Ghizlane BOUNDER, Institut Pasteur du Maroc and Faculty of Sciences Ben M’sik, University Hassan II, Morocco
    Place and role of radiation therapy in the treatment of thymic epithelial tumors
    Sara BELKHEIRI, CHU casablanca Maroc; centre Mohamed VI pour le traitement des cancers, Morocco
    Optimization of synchronization experiments using a checkpoint-oriented cell cycle simulator
    David BERNARD, ITAV & IRIT, France
    The DNA binding polyamine moiety in the vectorized DNA topoisomerase II inhibitor F14512 alters reparability of the consequent enzyme-linked DNA double strand breaks
    Patrick CALSOU, IPBS, CNRS, UMR5089, France
    Rapid detection of microRNA biomarkers through a nanofluidic-embedded biosensor coupled to molecular beacon probes
    Jean CACHEUX, CRCT-Inserm and LAAS-CNRS, France
    MacroH2A1.1, a new epigenetic target for treatment of prostate cancer.
    Anne-Claire LAVIGNE, Laboratoire de Biologie Moléculaire Eucaryote (LBME), Centre de Biologie Intégrative (CBI),, France
    Organotypic culture and 3D bioprinting of bone tumor models
    Pierre LAYROLLE, INSERM UMR1238, PHY-OS, University of Nantes, France
    Development and characterization of an extensive panel of patient-derived tumor xenograft (PDX) models for prostate, bladder and kidney cancers
    Claire BERAUD, UROLEAD, France
    Epidural metastasis of thyroid papillary carcinoma : A case report
    Sara BELKHEIRI, centre Mohemed VI pour le traitement des cancers CHu Casablanca, Morocco
    Marie-Noëlle PALUDETTO, INSERM, CRCT, France
    Longitudinal analysis of the effect of the Btk inhibitor ibrutinib on the motility properties of CLL leukemic cells and T cells
    Alice MUNARETTO, INSERM, France
    The Role of Oxidative Stress in Chemotherapy-Resistant Human Acute Myeloid Leukemia
    Mohsen HOSSEINI, CRCT- Inserm U1037, France
    Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients – OLA-TMZ-RTE-01 protocol
    Dinu STEFAN, Centre François Baclesse, France
    Preclinical evaluation of polyethylenimine-mediated RNA interference of Polo-Like Kinase 1 gene for ultrasound image-guided treatment of hepatocellular carcinoma
    Ghina BOUABOUT, IGBMC-ICS-Phenomin France, France
    The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors
    Pierre CORDELIER, Cancer Research Centre of Toulouse INSERM U1037, France
    Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.
    Coralie HOAREAU-AVEILLA, INSERM UMR1037, France
    Activation of MAPK and PI3K in melanoma
    Wafaa MAHFOUD, Laboratoire de Biologie et Santé, URAC-34, Faculté des sciences Ben M’sik, Université HassanII Mohammedia.-Casablanca, Morocco
    Dual metabolic functions of group IV cytosolic phospholipase A2 alpha (cPLA2?) in pancreatic ductal adenocarcinoma
    Christian VOLPOËT, U1068 CRCM, France
    A combined laser microdissection and proteomic analysis method for identification of robust biomarkers in oncology.
    Anne-Aurélie RAYMOND, Oncoprot U1053 TBM Core US005, France
    PARP-1-dependent induction of RND1 transcription confers cell resistance to the topoisomerase I inhibitor camptothecin
    Laetitia MOULY, INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France, France
    Louis BUSCAIL, Service de Gastroentérologie et Pancréatologie, CHU Toulouse Rangueil et Université Paul Sabatier Toulouse3, France
    Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach
    Loïc YSEBAERT, IUCT, France
    Combining TNF-targeting antibodies to immune checkpoint inhibitors in melanoma
    Anne MONTFORT, INSERM UMR 1037, Cancer Research Center, Toulouse, France
    Cedric BOULARAN, INVIVOGEN, France
    Inhibition of FGFR1 downregulates stemness, epithelial-mesenchymal transition associated genes and sensitizes glioblastoma tumor spheres to radiotherapy.
    Valérie GOUAZÉ-ANDERSSON, CRCT, France
    Sphingosine 1-Phosphate represses E-cadherin in epidermal keratinocytes and promotes migration of non-invasive melanoma cells
    Justine NOUJARÈDE, CRCT, France
    The role of Topoisomerase II-? (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer
    Mohamed GAMEA, aswan university, Egypt
  •  Programme Scientifique

    February 5, 2018 (9h00-12h00 A.M.) Metastasis and microenvironment – Metabolism  
    Metastasis & microenvironment
    Klaus Pantel (University Medical Center Hamburg-Eppendorf)

    Pierre Sonveaux (Université Catholique de Louvain)
    Matthew G Vander Heiden (MIT)
    Jean-Emmanuel Sarry (Cancer Research Center of Toulouse)

    February 5, 2018 (14h00-17h00 P.M.) Genetic instability and DNA damage response
    Jan Hoeijmakers (Erasmus University of Rotterdam)
    Steve Jackson (University of Cambridge)
    Jean-Marc Egly (IGBMC, Strasbourg)
    Mark O’Connor (Astra-Zeneca)
    Gaëlle Legube (Center for Integrative Biology, Toulouse)

    February 6, 2018 (9h00-12h00 A.M.) Epigenetics – Non coding genome and cancer
    With the support of
    Epigenetics (including epidemiology)
    Maarten van Lohuizen (The Netherlands Cancer Institute)

    Non-coding genome & cancer
    Ramiro Garzon (The Ohio State University)
    Maite Huarte (University of Navarra)
    François Payre (Center for Integrative Biology, Toulouse)

    February 6, 2018 (14h00-17h00 P.M.) Cancer Immunotherapy, from bench to bed 
    Jolanda De Vries (Radboud University Nijmegen)
    Nathalie Rufer (University of Lausanne)
    Jean-Philippe Girard (Institute of Pharmacology and Structural Biology, Toulouse)

    February 7, 2018 (9h00-12h00 A.M.) New therapeutic strategies
    Combined therapies
    Julien Mazières (IUCT-Rangueil Larrey, Cancer Research Center of Toulouse)

    Radiotherapy – Proton therapy
    Jim Metz (University of Pennsylvania)
    Gillies McKenna (University of Oxford)

    February 7, 2018 (14h00-17h00 P.M.) Clinical research on Melanoma
    Richard Marais (Cancer Research UK Manchester Institute)
    Céleste Lebbé (Hôpital Saint-Louis, APHP) 
    Nicolas Meyer (IUCT-Oncopole, Cancer Research Center of Toulouse)
    Comité local d'organisation :
    1 Av. Irène Joliot-Curie
    31100 Toulouse
    * prix depuis ligne fixe opérateur historique, une surtaxe peut être appliquée selon les opérateurs, décompte à la seconde au delà des 45 premières secondes.

    Conformément à la loi Informatique et Libertés, vous disposez d'un droit d'accès et de rectification aux données personnelles vous concernant en vous adressant à INSIGHT OUTSIDE 39 chemin du vieux chêne, 38240 Meylan / France. Conformément à la loi pour la Confiance dans l'Economie numérique du 21 juin 2004, vous pouvez également vous opposer à l'utilisation de vos coordonnées, en envoyant un simple courrier à l'adresse ci-dessus.

    © 2005 - 2019 Insight Outside